• Clearmind flagged positive early feedback from investigators in its ongoing first-in-human Phase I/IIa trial of CMND-100 (MEAI) for alcohol use disorder.
• Investigators cited a non-hallucinogenic profile that could support a simpler, more scalable treatment model than classical psychedelics.
• Early readouts indicated no meaningful adverse effects or cardiac safety concerns observed to date.
• Recruitment was progressing despite strict healthy-volunteer eligibility criteria.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-077542), on July 13, 2026, and is solely responsible for the information contained therein.